Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial

Giampaolo Cerisano, Piergiovanni Buonamici, Anna Maria Gori, Renato Valenti, Roberto Sciagrà, Betti Giusti, Alice Sereni, Silvia Raspanti, Paolo Colonna, Gian Franco Gensini, Rosanna Abbate, Richard Schulz, David Antoniucci

Research output: Contribution to journalArticlepeer-review

Abstract

Abstract Background The TIPTOP (Early Short-term Doxycycline Therapy In Patients with Acute Myocardial Infarction and Left Ventricular Dysfunction to Prevent The Ominous Progression to Adverse Remodelling) trial demonstrated that a timely, short-term therapy with doxycycline is able to reduce LV dilation, and both infarct size and severity in patients treated with primary percutaneous intervention (pPCI) for a first ST-elevation myocardial infarction (STEMI) and left ventricular (LV) dysfunction. In this secondary, pre-defined analysis of the TIPTOP trial we evaluated the relationship between doxycycline and plasma levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). Methods In 106 of the 110 (96%) patients enrolled in the TIPTOP trial, plasma MMPs and TIMPs were measured at baseline, and at post-STEMI days 1, 7, 30 and 180. To evaluate the remodeling process, 2D-Echo studies were performed at baseline and at 6 months. A 99mTc-SPECT was performed to evaluate the 6-month infarct size and severity. Results Doxycycline therapy was independently related to higher plasma TIMP-2 levels at day 7 (p <0.05). Plasma TIMP-2 levels above the median value at day 7 were correlated with the 6-month smaller infarct size (3% [0%-16%] vs. 12% [0%-30%], p = 0.002) and severity (0.55 [0.44-0.64] vs. 0.45 [0.29-0.60], p = 0.002), and LV dilation (- 1 ml/m2 [from - 7 ml/m2 to 9 ml/m2] vs. 3 ml/m2 [from - 2 ml/m2 to 19 ml/m2], p = 0.04), compared to their counterpart. Conclusions In this clinical setting, doxycycline therapy results in higher plasma levels of TIMP-2 which, in turn, inversely correlate with 6 month infarct size and severity as well as LV dilation.

Original languageEnglish
Article number20680
Pages (from-to)147-153
Number of pages7
JournalInternational Journal of Cardiology
Volume197
DOIs
Publication statusPublished - Aug 5 2015

Keywords

  • Acute myocardial infarction
  • Doxycycline
  • Infarct size
  • Left ventricular remodeling
  • Metalloproteinases
  • Tissue inhibitor of metalloproteinases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial'. Together they form a unique fingerprint.

Cite this